Sign Up to like & get
recommendations!
1
Published in 2019 at "Annals of Oncology"
DOI: 10.1093/annonc/mdz246.006
Abstract: Abstract Background We previously showed pTMB selects patients (pts) deriving benefit from PD-L1 and CTLA-4 inhibition with durvalumab and tremelimumab (D+T) compared to best supportive care (BSC) in refractory mCRC in CCTG CO.26. Methods We…
read more here.
Keywords:
mts;
ptmb;
dna repair;
mss ... See more keywords